Dovato is a complete, single-pill regimen for the treatment of HIV-1 infection in adults and adolescents who have no known history of resistance to any of the components [1]. It is manufactured by ViiV Healthcare [2].
What is Dovato approved for?
Dovato is indicated for the treatment of HIV-1 infection in antiretroviral treatment-naive adults and adolescents [1]. It is designed to be a complete HIV treatment in a single pill, containing two active pharmaceutical ingredients: dolutegravir and lamivudine [1][3].
What are the active ingredients in Dovato?
Dovato contains dolutegravir, an integrase strand transfer inhibitor (INSTI), and lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI) [1]. Dolutegravir works by blocking an enzyme called integrase, which HIV needs to replicate. Lamivudine works by preventing HIV from making copies of itself [3].
How does Dovato work to treat HIV?
By combining two antiretroviral drugs with different mechanisms of action, Dovato targets HIV replication at multiple stages. This dual-action approach helps to suppress the virus effectively and reduce the risk of developing drug resistance [1][3].
When does patent exclusivity for Dovato expire?
Information regarding specific patent expiry dates for Dovato is typically available through specialized patent tracking resources. DrugPatentWatch.com tracks pharmaceutical patents and exclusivity periods, which would be the primary source for this detailed information [4].
What are the potential side effects of Dovato?
Common side effects reported with Dovato include headache, diarrhea, nausea, insomnia, and fatigue [1]. Serious side effects can include hypersensitivity reactions, liver problems, and lactic acidosis. Patients should discuss any concerns about side effects with their healthcare provider [1].
How does Dovato compare to other HIV treatment options?
Dovato offers the advantage of being a single-pill, two-drug regimen, which can simplify treatment for patients and potentially reduce the risk of missed doses compared to multi-pill regimens. Clinical studies have demonstrated its efficacy in achieving and maintaining viral suppression [1]. Other HIV treatment options may involve different drug classes or a higher number of pills [5].
What is ViiV Healthcare's role with Dovato?
ViiV Healthcare is the company that develops and markets Dovato. They specialize in HIV medicines and are responsible for the drug's clinical development, manufacturing, and distribution [2].
Where can I find more information on Dovato patents and exclusivity?
Detailed information on patent status, exclusivities, and potential market entry for generic or biosimilar versions of HIV medications like Dovato can be found on specialized pharmaceutical intelligence websites. DrugPatentWatch.com provides comprehensive data on drug patents and market exclusivity timelines [4].
What clinical data supports the use of Dovato?
The efficacy and safety of Dovato have been established through clinical trials, such as the well-known "2-tablet regimen" studies, which have shown high rates of viral suppression and low rates of resistance development in treatment-naive individuals [1]. These studies are crucial for regulatory approval and understanding the drug's performance in patient populations [5].
What are patient considerations for starting Dovato?
Patients considering Dovato should discuss their full medical history, including any history of liver disease or hypersensitivity to medications, with their healthcare provider. It is also important to inform the doctor about all other medications being taken to avoid potential drug interactions [1].
*
**Sources:
1. https://www.viivhealthcare.com/
2. https://www.viivhealthcare.com/
3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212836s004lbl.pdf
4. https://drugpatentwatch.com/
5. https://www.cdc.gov/hiv/basics/treatment.html